GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2025
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Abstract readPractice Guideline
In one paragraph
Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- ESR Essentials: imaging of melanoma-practice recommendations by the European Society of Oncologic Imaging.European radiology · 2026Guideline
- Prognostic value of C-reactive protein in patients with melanoma: a meta-analysis.Annals of medicine · 2025Pooled it
- Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.Nature medicine · 2025Trial
- Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial.Journal of translational medicine · 2025Trial
- Primary isolated adrenal melanoma: A rare case report.Urology case reports · 2026Article
- Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).Nature medicine · 2026Article
- Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.International journal of cancer · 2026Article
- Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.Dermatology and therapy · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Review
- International Dermoscopy Society consensus recommendations for the management of lentigo maligna.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Immunogenic Cell Death in Melanoma Induced by Radiotherapy, Photodynamic Therapy, or Non-Thermal Plasma: The Role of Reactive Oxygen and Nitrogen Species.Biomedicines · 2026Review
- Review
- Review
- Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- [Oncologist's perspective from sentinel node biopsy of melanoma - three decades of experience].Magyar onkologia · 2026Review
- The Value of Adjuvant Radiotherapy in the Treatment of Melanoma: A Multi-Center Analysis.Cancers · 2026Article
- Survivorship care for melanoma patients: a scoping review.Journal of cancer survivorship : research and practice · 2026Review
- [TNM classification of melanoma : Evolution and limitations].Pathologie (Heidelberg, Germany) · 2026Review
- Tumor microenvironment and signaling pathways in melanoma brain metastasis.Annals of translational medicine · 2026Review
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
T AmaralSkin Cancer Clinical Trials Center-University of Tuebingen, Tuebingen, Germany.
M OttavianoDepartment of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.
A AranceDepartment of Medical Oncology and IDIBAPS, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain.
C BlankDepartment of Medical Oncology and Division of Immunology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Ziekenhuis (NKI), Amsterdam; Leiden University Medical Center (LUMC), Leiden, The Netherlands; University Clinic Regensburg, Regensburg, Germany.
V Chiarion-SileniDepartment of Oncology, Melanoma Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.
M DoniaNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark.
R DummerDepartment of Dermatology, Skin Cancer Center, USZ-University Hospital Zürich, University of Zürich, Zürich, Switzerland.
C GarbeDepartment of Dermatology, Center for DermatoOncology, University Hospital Tuebingen, Tuebingen, Germany.
J E GershenwaldDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center and The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, USA.
H GogasFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens-School of Medicine, Athens, Greece.
M GuckenbergerDepartment of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
J HaanenDivision of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Oncology Service, Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
O HamidMedical Oncology, Cutaneous Malignancies, The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Los Angeles, USA.
A HauschildDepartment of Dermatology, UKSH-Universitätsklinikum Schleswig-Holstein-Campus Kiel, Kiel, Germany.
C HöllerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
C LebbéUniversité Paris Cite, AP-HP Dermato-oncology and CIC, Cancer Institute APHP, Nord Paris Cité, INSERM U976, Saint Louis Hospital, Paris, France.
R J LeeDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
G V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Department Medical Oncology, Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
P LoriganDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
E Muñoz CouseloDepartment of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
P NathanMount Vernon Cancer Centre, Northwood, UK.
C RobertDepartment of Oncology, Institut Gustave Roussy and Paris-Saclay University, Villejuif, France.
E RomanoDepartment of Oncology, Center for Cancer Immunotherapy, Institut Curie, Paris, France.
D SchadendorfDepartment of Dermatology, WTZ-Westdeutsches Tumorzentrum Essen, National Center for Tumor Diseases (NCT-West), Campus Essen, Essen, Germany; University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.
V SondakDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, USA.
K P M SuijkerbuijkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
A C J van AkkooiMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
O MichielinDepartment of Oncology, Geneva University Hospital, Geneva, Switzerland.
P A AsciertoMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Instituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Funding
Wellcome Trust 225724
Abstract
PubMed holds no abstract for this paper.
Indexed as
cutaneous melanomadiagnosisESMO Clinical Practice Guidelineprognosisrisk assessmenttreatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.